Transmembrane peptides for immuno-oncology, oncology and immune diseases
This article was originally published in Start Up
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
You may also be interested in...
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.
Alcresta Pharmaceuticals Inc. aims to combat malabsorption, with an initial focus on enzyme deficiencies, for people with gastrointestinal disorders and rare diseases. It is developing a pipeline of point-of-care nutritional products tailored to maximize the absorption of calories or specific nutrients, based on cartridges enclosing enzymes immobilized onto polymer beads.